ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Metabolomics and Gut Microbiota in Elderly Patients with Diabetic Peripheral Neuropathy and Sarcopenia.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes peripheral neuropathy (DPN) is closely related to the occurrence and development of sarcopenia. However, the relevant early biological metabolites and their pathophysiological mechanism is unclear. Aim: To explore the underlying mechanisms of Diabetic Peripheral Neuropathy with Sarcopenia (DPNS) by integrating metabolomics and 16S rRNA sequencing. Methods: A total of 151 diabetic neuropathy patients were enrolled in the study. Untargeted metabolomics was performed using ultra-high-performance liquid. Chromatography-mass spectrometry, andgut microbiota was assessed through 16S rRNA sequencing. Differential metabolites and microbial taxa were identified, and theirassociations were explored using correlation analysis. Results: A total of 376 differential metabolites were identified. Compared with the DPN group, the contents of glycerophosphocholine(GPC), taurine, and succinic acid in the DPNS group were significantly decreased, while that of 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine(PhIP), Sphingosine were increased. Gutmicrobiota analysis revealed reduced diversity in DPNS, with decreased beneficial genera ( Conclusion: We systematically explored the biomarkers and potential therapeutic targets in the patients with DPNS, which may provide new insights that may advance the treatment of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.